Skip to content
EntityQ410435· pop 14· linked from 213 articles

benzbromarone

Sign in to save

Also known as 2-ethyl-3-(3,5-dibrom-4-hydroxybenzoyl)benzofuran, 3,5-dibromo-4-hydroxyphenyl-2-ethyl-3-benzofuranyl ketone, Uroleap (TN)

Benzbromarone is a uricosuric agent and weak non-competitive inhibitor of xanthine oxidase used in the treatment of gout. It is a brominated analogue of withdrawn uricosuric benziodarone and benzarone, and is structurally related to the antiarrhythmic amiodarone.

~5 min read

Encyclopedic overview

8 sections
Contents
  • Medical uses
  • Pharmacology
  • Mechanism of action
  • Pharmacokinetics
  • Side effects
  • Drug interactions
  • History
  • References

Benzbromarone is a uricosuric agent and weak non-competitive inhibitor of xanthine oxidase used in the treatment of gout. It is a brominated analogue of withdrawn uricosuric benziodarone and benzarone, and is structurally related to the antiarrhythmic amiodarone.

Benzbromarone was withdrawn from most European countries in 2003 due to the risk of idiosyncratic hepatotoxicity, but remains heavily used in Asia and South America. Despite this risk, it is generally considered highly effective and well tolerated in most patients. Clinical trials dating back to 1981 and as recent as 2022, as well as meta-analyses, have reported its superior efficacy compared to both non-uricosuric xanthine oxidase inhibitors (allopurinol and febuxostat) and another uricosuric drug, probenecid.

Excerpted from Wikipedia’s “benzbromarone” article, available under the CC BY-SA 4.0 licence.